Matthew W McCarthy
Matthew W McCarthy
Introduction: On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health (NIH) ...
Randomized Controlled Trial
Expert opinion on biological therapy. 2023 Jul-Dec;23(12):1211-1217. DOI:10.1080/14712598.2023.2296569 2023
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis [0.03%]
rozanolixizumab-noli治疗抗AChR和抗MuSK抗体阳性全身性重症肌无力的评估
Alexandria Matic,Nouf Alfaidi,Vera Bril
Alexandria Matic
Introduction: Myasthenia gravis (MG) is an auto-immune disease characterized by fluctuating symptoms of muscle weakness and fatigue. Corticosteroids and corticosteroid-sparing broad-spectrum immunosuppression play a great...
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning [0.03%]
CAR-T细胞疗法在DLBCL治疗中的应用：我们有哪些收获？
Massimo Martino,Filippo Antonio Canale,Gaetana Porto et al.
Massimo Martino et al.
Introduction: Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The weakness of CAR-T therapies ...
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET [0.03%]
发现新型cMET靶向抗体药物偶联物可望用于治疗高度表达cMET的实体瘤
Reyna Kv Lim,Matthew Buschman,Alisher Khasanov et al.
Reyna Kv Lim et al.
Background: Solid tumors are becoming prevalent affecting both old and young populations. Numerous solid tumors are associated with high cMET expression. The complexity of solid tumors combined with the highly interconnec...
Michail Alevizakos,David McDermott
Michail Alevizakos
Introduction: Locally advanced renal cell carcinoma (RCC) presents a therapeutic challenge due to 20-40% relapse risk post-nephrectomy. There has been substantial interest in utilizing immunotherapy interrupting the PD-1/...
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial [0.03%]
一种natalizumab类似物（PB006）与原研药在药代动力学和药效学的相似性：随机对照试验
Hendrik Wessels,Oliver von Richter,Maria Velinova et al.
Hendrik Wessels et al.
Background: PB006 (Polpharma Biologics S.A; marketed as Tyruko®, Sandoz) is an approved biosimilar to natalizumab (Tysabri®; Biogen [ref-NTZ]). This multicenter, double-blind, randomized, single-dose study was conducted...
Randomized Controlled Trial
Expert opinion on biological therapy. 2023 Jul-Dec;23(12):1287-1297. DOI:10.1080/14712598.2023.2290530 2023
Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London [0.03%]
真实世界数据评估乌司奴单抗治疗IBD患者有效性的回顾性研究：伦敦西北区数据库联合分析
Nik Kamperidis,Moulesh Shah,Sophie Young et al.
Nik Kamperidis et al.
Background: Data on the optimum positioning of biologics in the treatment of inflammatory bowel disease (IBD) are limited. Research design and methods: ...
Siddharth C Umarje,Sanjiban K Banerjee
Siddharth C Umarje
Introduction: The drying up of antibiotic pipeline has necessitated the development of alternative therapeutic strategies to control the problem of antimicrobial resistance (AMR) that is expected to kill 10-million people...
Daniel Wendling
Daniel Wendling
Introduction: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the elderly, treated mainly with systemic corticosteroids. The frequency of side effects of steroids is high in this aged population and i...
The history of Crohn's perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel [0.03%]
有关使用间充质干细胞治疗克罗恩病肛周瘘的历史：darvadstrocel的故事
Damian García-Olmo,Mariano Garcia-Arranz
Damian García-Olmo
Introduction: This study provides an overview of the development of the first drug authorized for use in cell therapy. Areas covered: W...